Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Human and Environmental Physiology Research Unit (HEPRU) at the University of Ottawa and Innovation Canada to work with SYMP2PASS by SmartCone on COVID screening enhancements

SmartCone Technologies, Inc.

Symp2Pass by SmartCone has partnered with the HEPRU in offering the first ever personal advanced COVID screening process using ScentsiBLE a patent pending smell test process. SmartCone Technologies, Canada’s leader in IoT (Internet of Things) solutions and developer of Symp2Pass is proud to announce a strategic partnership with Innovations Canada and Dr. Glen P. Kenny, Director of the HEPRU at the University of Ottawa, Canada to further develop technologies and proprietary processes to help strengthen the return-to-work solution for COVID-19. For the past 27 years, the HEPRU has been leading innovative and cutting-edge research on the assessment of the environmental and human factors affecting health and performance ( www.hepru.ca ). This includes the development of sophisticated heat protection technologies to safeguard health and safety in partnership with SmartCone Technologies. SmartCone Technologies and its strategic partners (like Disney SyncLink) have many valuable screening, monitoring and cleaning patents and processes that will be integrated into Symp2Pass and other processes to help in the prevention and spread of COVID-19 and protect the health and wellbeing of the general population and workers Symp2Passes by SmartCone is a personal and private advanced screening process that uses a patent pending smell test (ScentsiBLE) along with a key symptom survey and required government COVID questions to quickly test individuals for key symptoms of COVID. Symp2Pass is currently being tested by Disney, Ontario Tech University (funded by the Canadian Government) and a leading nuclear power company which, will increase safety for employees, site visitors and protect the assets (buildings, complexes etc.) so that everyone carry work responsibilities and socialize safely. “We are excited to work with Symp2Pass and SmartCone to help test, verify and finalize their COVID back-to-work screening process. In combination with a COVID self- assessment questionnaire, the system offers individuals a rapid screening test that can help stop the spread of COVID and keep individuals safe and workplaces open. “ Dr. Gen P. Kenny, Director of the HEPRU uOttawa” About SYMP2PASS Powered By SmartCone SYMP2PASS, developed in conjunction with doctors and researchers, is the first anonymous end-to-end advanced health screening web process. Using our patent pending ScentsiBLE scent test paired with multi-symptom survey, SYMP2PASS will help reduce the spread of COVID and save businesses and countries millions of dollars. Learn more at www.symp2pass.com About SmartCone Technologies, Inc. SmartCone Technologies Inc. (SCTI) is a unique data sensory company that commercializes new Internet-of-Things (IoT) technologies powering a wide array of sensors, edge computing, sensor fusion and artificial intelligence (AI). TheSmartCone™ solutions have been used most recently in “ Return to Work ” solutions during the COVID-19 pandemic, as well as securing dangerous work sites, controlling bicycle lane traffic, managing vehicle fleets, smart warehouses, crowd control, and more. Visit us at www.thesmartcone.com ### For more information, please contact Richard Harris 604-808-2124 ric@symp2pass.com Contact Details Symp2Pass Richard Harris CMO +1 604-808-2124 ric@symp2pass.com Company Website https://www.thesmartcone.com

June 23, 2021 01:56 PM Eastern Daylight Time

Image

Phase 4 Services Adds “Science and Quality Powerhouse” Duo to Roster of Cannabis Testing Experts

Phase 4 Services

MCR Labs Director of Scientific Operations Scott Churchill and former ANSI National Accreditation Board (ANAB) Accreditation Manager Matthew Sica have joined Phase 4 Services, a laboratory management and consulting firm looking to solidify its status as a leader in the marijuana and hemp testing space. Churchill, an analytical testing and pharmaceutical science expert with nearly a decade of cannabis industry experience, has been named Phase 4’s vice president of scientific development. Sica, a compliance testing and accreditation expert with 30 year of experience in the field, has joined the firm as vice president of regulatory compliance & quality. “Scott and Matt have both been integral to growing MCR Labs into a successful multistate organization,” said Michael Kahn, founder and CEO of MCR Labs, a cannabis testing lab operating in several legal cannabis markets. “Together, these two are an absolute science and quality powerhouse that bring critical knowledge and experience to Phase 4’s consulting team.” In their respective roles at Phase 4 Services, Churchill and Sica will assist the firm’s laboratory partners with method development, process improvement, regulatory compliance, and managing the challenges of scaling operations effectively. Phase 4 Services works with cannabis testing labs in both the marijuana and hemp industries to streamline management processes, advance testing capabilities, and implement business strategies designed for the evolving cannabis industry. About Phase 4 Services: Phase 4 Services is a scientific consulting and laboratory management firm dedicated to growing, supporting, and enhancing hemp and cannabis testing laboratories. Founded by experts in analytical testing, pharmaceutical chemistry, business administration, and development strategy, our team is equipped with the knowledge and experience necessary to ensure partner laboratories are successful in their pursuit of advancing public health and safety for cannabis patients and consumers. For more information visit http://phase4services.com. Contact Details Phase 4 Services Joe Crinkley +1 857-230-0839 PR@phase4services.com Company Website https://phase4services.com/

June 23, 2021 11:38 AM Eastern Daylight Time

CMS Renews Bellese Technologies Contract for Hospital Quality Reporting (HQR)

Bellese Technologies, LLC

The Centers for Medicare & Medicaid Services (CMS) awarded Bellese Technologies the Hospital Quality Reporting (HQR) II contract. Bellese is the incumbent prime contractor for this project and has been awarded the HQR contract for the second time. This contract period consists of one base-period with three additional option-years. Under the direction of the Center for Clinical Standards and Quality's (CCSQ) Information Systems Group (ISG), Bellese worked closely with CMS to modernize the legacy HQR system using modern digital service methods. Pam Offutt, Bellese Chief Executive Officer, stated that “The past four years of partnership with CMS on the HQR system have been incredibly rewarding. We have made significant progress in the modernization of HQR and in the adoption of agile, lean, and human-centered design methods. Through this work, we are paving the way for CMS, other agencies, and their users to enjoy better performing and more usable services.” "With improved access to hospital quality measure data and participation in data interoperability initiatives, HQR II will reduce barriers between patients, healthcare providers and policy makers," said John duClos, Bellese Chief Technology Officer. The CMS and Bellese partnership has a history of producing meaningful results. In the initial contract period, the Bellese team completed modernization of the HQR infrastructure. The HQR system is now entirely hosted on cloud infrastructure. The time it took users to generate reports dropped dramatically from over 24 hours in the legacy system to approximately one second in the new system. Previously, downtime was required for almost all system updates and maintenance. Legacy system deployments could take over 20 hours to complete. Now, updates and maintenance can be done with zero downtime and no impact to users. In the first two years of the HQR contract, Bellese saved CMS nearly $1M as a result of system optimizations and automations. “I've worked on HQR for 11 years in different roles. It wasn't until I joined Bellese five years ago when we really started to make significant progress on enhancements through the use of research, design thinking and product development methodologies,” said Karen Waters, Bellese Program Director of HQR. “From our focus on human-centered design to using modern technology while also successfully maintaining all that legacy code, the HQR team tackled some extraordinary challenges. I am extremely proud to work alongside each of our team members, CMS, support contractors, and the HQR users.” The modernization of HQR is part of a larger CMS initiative called Patients over Paperwork. This initiative seeks to increase efficiencies, improve the end-user experience for end-users, and lower the overall provider burden. HQR allows facilities to directly report their quality measures. This reduction in time to use the system and submit data is now precious time gained by hospital staff to spend on their main job -- running a hospital and caring for patients. At Bellese the process of reducing burden started with understanding the people using the system, their environment, and importantly, their behavior. “Fundamentally we want to make using the system as easy to use as possible.“ said Lesley Humphreys, Bellese Human-Centered Design Lead for HQR. “We did that through multiple research methods and ensuring our researchers, designers, and developers worked as one to meet user needs.” Together, CMS and Bellese achieved the goal of legacy system modernization and positioning the HQR program for its role in the future of digital quality measurement. The HQR ecosystem includes several federal incentive programs including: Inpatient Quality Reporting (IQR), Outpatient Quality Reporting (OQR), Inpatient Psychiatric Facility Quality Reporting (IPF), PPS-Exempt Cancer Hospital Quality Reporting (PCH), and Ambulatory Surgical Center Quality Reporting (ASC). All of these incentive programs are supported by the HQR solution. ABOUT BELLESE TECHNOLOGIES: Founded in 2009, Bellese Technologies is a human-centered service design company in the Baltimore metro area. Bellese partners with health and human services clients in the public and private sectors. The firm leverages modern technology, human-centered design, and silo-busting collaboration to help its clients expand and accelerate the positive impact they have on society. Currently, Bellese works with the Centers for Medicare & Medicaid Services, supporting price transparency, Medicare payment system modernization, and quality of care initiatives.Bellese holds the GSA IT 70 Schedule and two CMS agile blanket purchase agreements (BPA) — the Medicare Payment System Modernization (MPSM) BPA and the Agile Delivery to Execute Legislative Endeavors-Quality Related Initiatives (ADELE-QRI) BPA. Bellese was recently recognized as a “Top Workplace” by the Baltimore Sun for the third year in a row. Visit bellese.io/careers for more information on careers at Bellese. Contact Details Bellese Technologies Mark Adkins +1 202-335-0065 press@bellese.io Company Website https://bellese.io/

June 22, 2021 12:35 PM Eastern Daylight Time

Cloudrise Closes Seed Round of Funding

Cloudrise

Cloudrise accelerates growth in 2021 by closing out their seed round of funding, recruiting new talent to their board of directors, fostering core partnerships, and delivering best-in-class data protection and automation services to their customers. Since launching the company in October of 2019, Cloudrise has delivered 100+ data protection services projects to over 60 customers globally, including several Fortune 50 enterprises. As they continue to exceed revenue targets and the momentum builds, Cloudrise is investing significantly to expand their service delivery and research and development teams, raising the bar for data protection and automation. In May, Cloudrise secured additional capital to help to fund further growth and innovation. Stormbreaker Ventures is a key investor that helped enable Cloudrise to close the seed round of investment funding. Said Mia, Managing Partner at Stormbreaker, commented: “Cloudrise’s vision of redefining data protection through automation is unmatched in this space and we are confident their innovative drive, coupled with Stormbreaker’s investment, will propel the team into their next phase of growth. We look to partner with high-velocity companies that build effectively and efficiently, and Cloudrise's approach to date has been the best of both." With success comes the need to add more talent to the Board of Directors. A Partner at Greater Colorado Venture Fund, Marc Nager also co-founded Startup Weekend, was CEO of UP Global, and Chief Community Officer at Techstars. Marc not only brings a wealth of experience to the board, but his passions for the Western Slope of Colorado align with Cloudrise’s drive to provide opportunities within their community. “I am honored and excited to join such a passionate and innovative team. I feel strongly that this team is at the right place, at the right time in the cyber security space, and we know the Western Slope startup community is going to rally behind the amazing team they're building in Grand Junction,” said Marc Nager. Cloudrise is committed to delivering high-value, innovative solutions to their customers. “We are extremely excited to welcome Marc to the board and Stormbreaker to our investment portfolio. These partnerships will enable Cloudrise to continue to innovate and provide world-class services to our customers. We founded Cloudrise on the premise that we want to provide value to our customers every day – and for us that means maintaining genuine culture, partnering with our customers, and driving innovation based on business needs”, said Rob Eggebrecht, CEO and co-founder at Cloudrise. About Stormbreaker Ventures Stormbreaker Ventures is an early-stage fund focused on capital efficient startups. The firm believes in a future where venture capital is more equitable, more efficient, and more genuine. Stormbreaker sees an opportunity within venture capital to be a true partner to its founders, not just a check that bides time until the next round. With a portfolio of more than 30 companies, Stormbreaker's partners operate from Silicon Valley, Denver, and Houston. About Marc Nager Marc is a Partner at the Greater Colorado Venture Fund and since 2009, Marc has been a leader of the startup movement around the world. He has built and scaled programs that have served more than 500,000 entrepreneurs in over 700 cities and 142 countries around the world. At UP Global he managed a team of nearly 75 people with offices in 5 international locations and oversaw Startup Weekend, Startup Next, Startup Digest, Startup Week, and Startup America. He's worked with grassroots and political leaders from around the world as well as executives at many FT500 companies around innovation and entrepreneurship. Originally from the small town of Mammoth Lakes, CA, Marc now lives in Telluride where he served as the Managing Director for the Telluride Venture Accelerator. When he is not working to change the state of rural economies, he can be found out in the mountains. About Cloudrise Cloudrise was founded by business and security entrepreneurs with experience in global markets, successful start-ups, and Fortune 500 companies. Combining decades of data protection expertise with automation, Cloudrise focuses on securing data wherever it resides. They assist organizations by assessing, enabling, automating, and managing their data protection and privacy programs. At Cloudrise, they are redefining data protection. Cloudrise can be found at www.cloudrise.com or on LinkedIn. Contact Details CLoudrise, Inc. Jodi Lewis +1 800-917-7619 sales@cloudrise.com Company Website https://cloudrise.com/

June 22, 2021 11:11 AM Central Daylight Time

Rani Therapeutics Appoints Talat Imran CEO

Rani Therapeutics

Rani Therapeutics, a disrupter in oral biologics, today announced the appointment of Talat Imran to Chief Executive Officer. Mir Imran, the company’s founder and former CEO, will become Executive Chairman. “Talat has extensive experience in corporate development and fundraising and has been actively involved in Rani’s key strategic decisions for many years. His appointment as CEO is a natural evolution of the leadership he has demonstrated during his tenure with the company,” said Maulik Nanavaty, Rani Board member. “We are incredibly grateful for Mir’s many contributions to the company, and his commitment and leadership since founding Rani.” “I am honored to be appointed CEO of Rani Therapeutics – a company that I believe has the potential to reinvent, disrupt and expand the biologics industry as we currently know it,” said Talat Imran, Rani’s CEO. “Mir has an amazing track record of innovation and entrepreneurship, and I’m delighted that he will continue to be engaged with the further development of our RaniPill™ platform.” Talat has been a key member of Rani’s executive team since 2014, most recently serving as the company’s Vice President, Strategy. In addition to his role at Rani, Talat has been a venture capitalist with several healthcare-focused Silicon Valley funds, including InCube Ventures, LP, and VentureHealth. Previously, he also served as Chief Executive Officer of Venture Web Partners, a web application development firm. “We believe passionately in our goal of transforming the lives of millions of patients who currently must endure injectable therapies,” said Mir Imran, Rani’s founder and Executive Chairman. “Talat deeply understands Rani’s business and the opportunities that lay ahead of us, and he is uniquely positioned to lead and guide us through the next stages of our development.” About Rani Therapeutics Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. The company has developed the RaniPill™ capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule. Investor Contact: investors@ranitherapeutics.com Media Contact: rani-therapeutics@consortpartners.com Contact Details Consort Partners rani-therapeutics@consortpartners.com

June 22, 2021 11:00 AM Eastern Daylight Time

How AI is Helping the Fight Against Breast Cancer

YourUpdateTV

Breast cancer recently surpassed lung cancer as the number 1 diagnosed cancer in the U.S., excluding nonmelanoma skin cancer. Additionally, the National Cancer Institute recently predicted an almost 10,000 excess deaths from breast and colorectal cancers over the next 10 years as a direct result of the pandemic, making it now more important than ever for women to take control over their breast health. Recently, Randy Hicks, MD, MBA, Co-Owner and CEO of Regional Medical Imaging (RMI) in Michigan, participated in a nationwide satellite media tour to discuss how new technology is helping the fight against breast cancer. A video accompanying this announcement is available at: https://youtu.be/7nWf973J1ww The COVID-19 pandemic brought routine health screenings, such as mammograms, to a screeching halt, declining up to 92% in some areas last year, according to a study in the Journal of the American College of Radiology. Now, with Americans getting vaccinated and infection rates decreasing around the country, many women are playing catch-up on these vital health screenings, which leads to another issue — a drastic increase in workload for doctors, who must face a surge of patients who need to be screened. Fortunately, an innovative new tool is available to help clinicians cope with this sudden demand, which at the same time provides them a higher degree of accuracy than ever before. ProFound AI ® uses the latest in deep-learning artificial intelligence (AI) and is clinically proven to help radiologists read mammograms more than 50% faster - and with more accuracy - while also reducing false positives and unnecessary callbacks, which can be stressful for women. ProFound AI was the first 3D tomosynthesis software using AI to be cleared by the FDA. For more information, visit icadmed.com About Randy Hicks, MD, MBA, Co-Owner and CEO of Regional Medical Imaging (RMI) in Michigan: Dr. Hicks is a distinguished practitioner, thought leader, and published researcher in women’s imaging for breast cancer, with additional interests and expertise in parathyroid and thyroid imaging, and in developing interventional breast biopsy procedures and products. A committed advocate for women’s healthcare, Dr. Hicks has worked closely with colleagues in the medical community to encourage multidisciplinary, best-practice approaches, having collaborated to establish local tumor boards that pool expertise from leading healthcare organizations in the region. He has also served as a catalyst for expanding the role of information technology and the use of artificial intelligence in enhancing the quality and efficiency of healthcare. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 18, 2021 10:00 AM Eastern Daylight Time

Video

Code 1 Supply Named Distributor for SCoV-2 Ag Detect™ Rapid Test for COVID-19 from InBios

Code 1 Supply

Code 1 Supply, a leading distributor of best-in-class medical diagnostics, brand-name supplies and equipment and provider of CPR training equipment and student materials, has been named distributor of an innovative new point-of-care COVID-19 test, the SCoV-2 Ag Detect ™ Rapid Test from InBios International, Inc. The SCoV-2 Ag Detect ™ Rapid Test is a patent-pending lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleoprotein antigen in direct nasal swab specimens. The point-of-care test can be used to evaluate both symptomatic and asymptomatic individuals. The test can be used for those who are suspected of COVID-19 by their healthcare provider within five days of symptom onset or for individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. The kit contains 50 tests and swabs, positive and negative controls and can be stored at room temperature. “As more Americans receive their COVID-19 vaccine, we are seeing a return to normalcy, which must still be supported by testing,” said Matt Regan, CEO at Code 1 Supply. “We are proud to partner with InBios to supply the SCoV-2 Ag Detect ™ Rapid Test nationwide to quickly and easily detect proteins from COVID-19 infection.” Code 1 Supply delivers best-in-class medical diagnostics and brand-name supplies and equipment when and where they are needed most. Code 1 Supply carries innovative next-generation rapid diagnostics for accurate, low-cost, high volume COVID-19 testing and provides exceptional customer service and expertise. They have been a leader in COVID-19 testing since the beginning of the pandemic, helping to supply medical professionals with sufficient testing supplies and equipment worldwide. Now, with FDA Emergency Use Authorization of the SCoV-2 Ag Detect ™ Rapid Test, Code 1 Supply is prepared to ship millions of tests to fulfill ongoing needs. “We are pleased to collaborate with Code 1 Supply as our e-commerce distribution partner to quickly expand accessibility and extend our reach to POC providers with a much simpler option for rapid antigen detection than they may have had access to previously,” said Estela Raychaudhuri, President, at InBios. “Code 1 Supply’s superior customer service and easy to navigate ordering process is an important part of providing access to incredibly accurate diagnostic tests that make a meaningful difference in people’s lives as they return to their jobs, schools and other ways of life.” The point-of-care SCoV-2 Ag Detect ™ Rapid Test is available through Code 1 Supply. To learn more about how Code 1 Supply can support your COVID-19 testing needs, please visit www.code1supply.com/inbiosagdetect. The SCoV-2 Ag Detect ™ Rapid Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. About Code 1 Supply Code 1 Supply is an international distributor of best-in-class medical diagnostics, brand-name supplies, and equipment, and a leading provider of CPR training equipment and student materials. Representing the most trusted and respected manufacturers of medical diagnostics, supplies and equipment, Code 1 Supply is committed to providing innovative products and outstanding services at the best prices. We are proud to be the medical supply partner for healthcare providers, hospitals, urgent care centers, businesses and communities worldwide. For more information, visit www.code1supply.com. About InBios InBios International Inc. specializes in the design, development and manufacture of diagnostic assays for emerging infectious diseases and biothreats. Located in Seattle, WA, InBios offers superior quality products which are accurate, easy to use and cost effective. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit http://www.inbios.com. # # # Contact Details SVM PR and Marketing Rita Murphy +1 774-454-1516 rita.murphy@svmpr.com Company Website https://www.code1supply.com/

June 17, 2021 10:42 AM Eastern Daylight Time

New Markets Tax Credit Coalition Releases 2021 NMTC Progress Report

New Markets Tax Credit Coalition

The New Markets Tax Credit Coalition today released its 2021 New Markets Tax Credit (NMTC) Progress Report, the seventeenth edition of the report—providing analysis of NMTC activities in 2020. The report was prepared by the NMTC Coalition, a national membership organization of Community Development Entities (CDEs) and investors organized to advocate on behalf of the NMTC. Every year since 2005, the NMTC Coalition surveys CDEs on their work delivering billions of dollars to businesses, creating jobs, and rejuvenating the parts of the country that have been left behind. The annual NMTC Progress Report presents the findings of the CDE survey and provides policymakers and practitioners with the latest trends and successes of the NMTC. "The Coalition's annual survey asks CDEs to report on the deployment of their allocation, investor trends, and a variety of community impact metrics," said Yvette Ittu, NMTC Coalition Board Chair and the President of Cleveland Development Advisors, a CDE in Cleveland, Ohio. "The findings clearly demonstrate the continued improvement and refinement of the program's efficiency and impact in low-income communities. Two decades after its introduction, the NMTC is no longer simply just a tool for delivering investment – instead, it has become one of the federal government's most effective tools for job creation and economic stabilization." Report highlights include: CDEs used $2.9 billion in NMTC allocation in 2020 to finance 272 NMTC projects in 48 states, Puerto Rico and the District of Columbia, amounting to $5.5 billion in total project investment to low-income communities. This financing resulted in the creation of 45,090 total jobs, including 28,322 permanent full-time-equivalent jobs and 16,768 construction jobs. Across 46 states and territories, CDEs rehabilitated or constructed 15.4 million square feet of space in 2020, thanks to NMTC financing. 82 projects expanded healthcare access in 2020 for 1.3 million patients. Healthcare projects included 41 Federally Qualified Health Centers and free clinics. 188 million meals were provided by food banks, food pantries, and community food projects financed in a year marked by an increase in food insecurity. More than 84,000 children in schools, youth programs and childcare centers were served. NMTC financing supported 152 manufacturing and industrial businesses with loans for working capital, new equipment, and 5.5 million sq. ft. of new space, often through incubators and multi-business facilities, creating 9,298 manufacturing jobs. 61 percent of mixed-use projects included at least one community facility, nonprofit, or social service component. Those new community resources add up to over 408 nonprofit facilities, health centers, childcare centers, libraries, community centers, and other community facilities. 85 percent of projects were in severely distressed communities. Sixty CDEs participated in the 2021 survey and provided data on their progress raising capital, lending, and investing in 2020 with the NMTC. The survey findings show that competition for credits continues to drive gains in efficiency. "Year after year, the data shows the NMTC not only delivers an unprecedented level of capital to low-income rural and urban communities, but it also creates much-needed jobs—helping individuals and families thrive and, in turn, grows those local economies where they live and work. In fact, since 2003, the NMTC has created more than one million jobs. Communities that were already struggling have been hit hard by the COVID-19 pandemic and need this important incentive for community revitalization now more than ever," said Coalition spokesperson Bob Rapoza. The report showcases the importance of the NMTC in providing more than two decades worth of patient, flexible capital to businesses and projects located in distressed rural and urban communities, thereby creating jobs and growing business opportunities. The NMTC financing ranges from more traditional industry and community sectors to new and cutting-edge technology. Projects and businesses that benefited from the Credit in the past year include manufacturing, healthcare, schools, and many others supporting childcare, youth, and families. Rapoza notes, "This report is further proof that the NMTC is working and Congress should expand and make the Credit permanent. It has the potential to positively impact communities across the country for years to come." About New Markets Tax Credit Program The New Markets Tax Credit (NMTC) was enacted in 2000 in an effort to stimulate private investment and economic growth in low-income urban neighborhoods and rural communities that lack access to the patient capital needed to support and grow businesses, create jobs, and sustain healthy local economies. Since its inception, the NMTC has generated more than one million jobs. Today, due to the NMTC, nearly $110 billion is hard at work in underserved communities in all 50 states, the District of Columbia, and Puerto Rico. For more information, visit www.NMTCCoalition.org. Contact Details Greg Wilson +1 571-239-7474 greg@curleycompany.com Company Website http://nmtccoalition.org/

June 17, 2021 09:00 AM Eastern Daylight Time

American Kidney Fund Applauds Introduction of the CARE for All Kidneys Act of 2021

American Kidney Fund

The American Kidney Fund (AKF) applauds Reps. Lisa Blunt Rochester (D-DE) and Brad Wenstrup (R-OH) for introducing the Coordination, Accountability, Research and Equity for All Kidneys Act of 2021, also known as the CARE for All Kidneys Act of 2021 (H.R. 3893). The bill would create a national action plan to address kidney disease in historically underserved populations, including minority and rural communities. LaVarne A. Burton, president and CEO of the American Kidney Fund, today issued this statement: “Kidney disease is one of the top 10 leading causes of death in the United States. Communities of color are disproportionately impacted by kidney failure, and underserved and rural communities face issues accessing health care. This important bill will pinpoint the issues that have created such a burden of kidney disease in these communities and will develop steps needed to prevent kidney disease, delay progression to kidney failure and increase the number of kidney transplants. “People living in underserved and rural communities have long faced challenges accessing health insurance, primary care, preventive care and pre-dialysis nephrology care. AKF is proud to have worked closely with Reps. Blunt Rochester and Wenstrup to develop a bill that aims to improve the health care delivery system, making it more equitable, accessible and inclusive, and to ensure high quality care for all kidney disease patients. “The CARE for All Kidneys Act of 2021 would create a national action plan that brings together key stakeholders, including the National Institutes of Health (NIH), the National Institute of Diabetes and Digestive and Kidney Diseases at NIH and the Centers for Disease Control and Prevention to address health disparities in kidney disease. The bill would support initiatives like expanding ongoing kidney disease research and addressing lower kidney transplantation rates in underserved communities. “This legislation is vital in addressing health disparities, improving the social determinants of health in the U.S. and ensuring that all kidney patients have access to the care they need. The introduction of this bill is just the first step. AKF is urging other members of Congress to cosponsor this important legislation to help it advance.” About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details American Kidney Fund Elissa Blattman +1 301-984-6644 eblattman@kidneyfund.org Company Website http://www.kidneyfund.org/

June 17, 2021 09:00 AM Eastern Daylight Time

1 ... 265 266 267 268 269 ... 302